Results 61 to 70 of about 1,159,973 (256)

Outcomes in progressive pulmonary fibrosis in systemic autoimmune rheumatic diseases: real‐world data from the ILD‐PRO Registry

open access: yesArthritis &Rheumatology, Accepted Article.
Objective We evaluated baseline characteristics, treatment patterns, and outcomes in patients with systemic autoimmune rheumatic disease‐associated progressive pulmonary fibrosis (SARD‐PPF) and evaluated whether outcomes differed by SARD subtype. Methods The ILD‐PRO Registry is a prospective multicenter US registry of patients with PPF.
Sonali J Bracken   +7 more
wiley   +1 more source

Updated COVID‐19 Vaccines and Health Outcomes in Patients With Autoimmune Rheumatic Conditions

open access: yesArthritis &Rheumatology, EarlyView.
Objective We aimed to assess the association between COVID‐19 vaccination status and COVID‐19‐related hospital admissions, need for mechanical ventilation or extracorporeal membrane oxygenation (ECMO), and death in people with autoimmune rheumatic conditions. Methods We conducted a retrospective cohort study using National Clinical Cohort Collaborative
Lesley E. Jackson   +127 more
wiley   +1 more source

Single‐cell RNA sequencing of peripheral blood defines two immunological subtypes of Sjögren's disease distinguished by anti‐SSA antibodies and aberrant B cell populations

open access: yesArthritis &Rheumatology, Accepted Article.
Objectives Sjögren's disease (SjD) is a heterogeneous autoimmune disorder characterized by substantial clinical and molecular diversity. This heterogeneity raises key questions regarding the existence of distinct pathogenic mechanisms underlying disease subtypes.
Geoffrey Urbanski   +15 more
wiley   +1 more source

Shared and Distinguishing Features of Late‐Onset Rheumatic Diseases Fulfilling Polymyalgia Rheumatica Classification Criteria

open access: yesArthritis &Rheumatology, Accepted Article.
‐
Kerem Abacar   +5 more
wiley   +1 more source

Treatment‐driven peripheral blood transcriptomic remodelling and baseline predictors of ESSDAI and STAR response to B‐cell therapy in Sjögren's disease

open access: yesArthritis &Rheumatology, Accepted Article.
Objective To characterise whole‐blood transcriptomic profiles in adults with active Sjögren's disease (SjD) treated with anti‐CD20 or BlyS/BAFF inhibition, identify markers of clinical response, and define inflammatory pathways linked to non‐response. Methods Whole‐blood RNA sequencing was performed at baseline and week‐24 in participants (n=43) from a
Aimen Ibrahim   +9 more
wiley   +1 more source

Quantitative Assessment of Salivary Gland Parenchymal Vascularization Using Power Doppler Ultrasound and Superb Microvascular Imaging: A Potential Tool in the Diagnosis of Sjögren"s Syndrome

open access: yesBalkan Medical Journal, 2020
Background: Primary Sjögren’s syndrome is a chronic inflammatory autoimmune disease. Minor salivary gland biopsy is the gold standard for the diagnosis of primary Sjögren’s syndrome.
Fethi Emre Ustabaşıoğlu   +6 more
doaj   +1 more source

Role of ncRNAs in the Pathogenesis of Sjögren’s Syndrome [PDF]

open access: yes
Sjögren’s syndrome is a multisystemic autoimmune disease that mainly affects the exocrine glands, causing dryness of the eyes and the mouth as the principal symptoms.
Mahmoud Elhassan   +17 more
core   +1 more source

Increased Risk of Glaucoma in Patients with Sjögren’s Syndrome: A Nationwide Population-Based Cohort Study

open access: yes, 2023
The risk of glaucoma in patients suffering from Sjögren’s syndrome has not been elucidated. We aimed for evaluating the absolute incidence as well as the relative risk of glaucoma in patients with SS at the level of the whole country population.
Chi-Hsiang Chung (306301)   +4 more
core   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun   +4 more
wiley   +1 more source

Targeting chronic fatigue in Sjögren’s syndrome [PDF]

open access: yes, 2021
This booklet offers tips for targeting chronic fatigue in Sjögren’s syndrome. First, personal factors that can influence fatigue are mapped.
Clinical Psychology (onderzoeksprogramma)   +2 more
core   +1 more source

Home - About - Disclaimer - Privacy